Lynx1 Capital Management LP Allogene Therapeutics, Inc. Transaction History
Lynx1 Capital Management LP
- $338 Million
- Q2 2025
A detailed history of Lynx1 Capital Management LP transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 11,057,009 shares of ALLO stock, worth $12.3 Million. This represents 3.7% of its overall portfolio holdings.
Number of Shares
11,057,009
Previous 11,057,009
-0.0%
Holding current value
$12.3 Million
Previous $16.1 Million
22.6%
% of portfolio
3.7%
Previous 5.97%
Shares
4 transactions
Others Institutions Holding ALLO
# of Institutions
169Shares Held
162MCall Options Held
146KPut Options Held
97.1K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$20.8 Million1.28% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$18.3 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA11.2MShares$12.4 Million0.0% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y910.5MShares$11.6 Million0.5% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il10.3MShares$11.4 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $160M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...